Current approaches to treatment of antiphospholipid syndrome during pregnancy: a case report

The article presents a clinical case of a patient with antiphospholipid syndrome (APS), with a history of deep vein thrombosis and recurrent miscarriage. The methods of additional therapy for APS during pregnancy, which are used in cases of miscarriage refractory to the standard treatment, are described: administration of intravenous immunoglobulin, plasma exchange, glucocorticosteroids. The literature data on the use of additional APS therapy in pregnancy are given.

Download Full-text

Antiphospholipid Syndrome – Early Pregnancy Loss

Asian Journal of Nursing Education and Research ◽

10.52711/2349-2996.2021.00136 ◽

2021 ◽

pp. 585-590

Author(s):

Neeta Thakur

Keyword(s):

Deep Vein Thrombosis ◽

Antiphospholipid Syndrome ◽

Pregnancy Loss ◽

Recurrent Pregnancy Loss ◽

Annual Incidence ◽

Obstetric Outcome ◽

Immune Disorder ◽

Vein Thrombosis ◽

History Of ◽

Deep Vein

Antiphospholipid syndrome (APLS) is an acquired is auto immune disorder that is defined by the presence of antibodies known as antiphospholipid antibodies in addition to clinical thrombosis and/ or poor obstetric outcome. Although the incidence remains unknown, 10% to 15% of women with a history of recurrent pregnancy loss will meet the criteria for APLS. In these Patients, the annual incidence of deep vein thrombosis and stroke is 1.46% and 0.32% respectively. Compared with the annual incidence in the general population of 0.1% for deep vein thrombosis and 0.1% for stroke.1

Download Full-text

Risk Factors for Deep Vein Thrombosis in Pregnancy and Puerperium at a Tertiary Care Hospital in Muzaffarabad, AJK

10.53350/pjmhs2115123191 ◽

2021 ◽

Vol 15 (12) ◽

pp. 3191-3192

Author(s):

Mudasar Hafiz ◽

Muanzza Nazir ◽

Syeda Abida Hussain ◽

Rubina Rafique ◽

Nosheena Shabir ◽

...

Keyword(s):

Diabetes Mellitus ◽

Risk Factors ◽

Deep Vein Thrombosis ◽

Gestational Diabetes ◽

Past History ◽

Third Trimester ◽

Vein Thrombosis ◽

History Of ◽

Deep Vein ◽

In Pregnancy

Aim: Risk factors of deep vein thrombosis in pregnancy and puerperium in our setting. Study Design: Descriptive Cross-sectional study Place and duration of study: Departments of Obs & Gynae and General Medicine, CMH Muzaffarabad, AJK from 20th December, 2019 to 20th June, 2020. Methodology: A total of 385 females were included. Demographic data including age, parity, gravidity, BMI, obesity and timing of DVT occurrence was noted. The associated risk factors including mode of delivery in postpartum women, smoking status, past history of DVT, gestational diabetes and Diabetes Mellitus were noted. Results: Mean age of the participants was 26.1±5.3 years. Frequency of women developing deep vein thrombosis during pregnancy was 84.9% and 15.1% women developed DVT during puerperium. Past history of DVT was present in 26.5%. 31.7% of women were known diabetics and 29.1% developed gestational diabetes during current pregnancy. Frequency of smoking was 4.2%. 8% women presented with DVT in first trimester, 139(36.1%) in second trimester and 154 (40%) in third trimester. Conclusion: DVT is more common in the third trimester of pregnancy than in puerperium. Obesity, Diabetes Mellitus and past history of DVT were significant risk factors identified in the study. Keywords: Pregnancy, Postpartum Period, Deep Vein Thrombosis

Download Full-text

Faculty Opinions recommendation of Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13489038.14866158 ◽

2012 ◽

Author(s):

Norman Hertzer

Keyword(s):

Deep Vein Thrombosis ◽

Standard Treatment ◽

Controlled Trial ◽

Term Outcome ◽

Long Term Outcome ◽

Vein Thrombosis ◽

Catheter Directed Thrombolysis ◽

Randomised Controlled ◽

Deep Vein

Download Full-text

P-089 Upper limb deep vein thrombosis in pregnancy (ULDVT): Case report of 4 patients

Thrombosis Research ◽

10.1016/s0049-3848(13)70135-x ◽

2013 ◽

Vol 131 ◽

pp. S99

Author(s):

M. Casellas ◽

S. Capote ◽

A. Correa ◽

F. Pérez-Ceresuela ◽

L. Cabero

Keyword(s):

Deep Vein Thrombosis ◽

Case Report ◽

Upper Limb ◽

Vein Thrombosis ◽

Deep Vein ◽

Limb Deep Vein Thrombosis ◽

In Pregnancy

Download Full-text

A murine model of deep vein thrombosis Characterization and validation in transgenic mice

Thrombosis and Haemostasis ◽

10.1160/th05-03-0170 ◽

2005 ◽

Vol 94 (09) ◽

pp. 498-503 ◽

Cited By ~ 25

Author(s):

Linda Szema ◽

Chao-Ying Chen ◽

Jeffrey P. Schwab ◽

Gregory Schmeling ◽

Brian C. Cooley

Keyword(s):

Deep Vein Thrombosis ◽

Murine Model ◽

Femoral Vein ◽

Previous History ◽

Bed Rest ◽

Major Surgery ◽

Vein Thrombosis ◽

Transgenic Lines ◽

History Of ◽

Deep Vein

SummaryDeep vein thrombosis (DVT) occurs with high prevalence in association with a number of risk factors, including major surgery, trauma, obesity, bed rest (>5 days), cancer, a previous history of DVT, and several predisposing prothrombotic mutations. A novel murine model of DVT was developed for applications to preclinical studies of transgenically constructed prothrombotic lines and evaluation of new antithrombotic therapies. A transient direct-current electrical injury was induced in the common femoral vein of adult C57Bl/6 mice. A non-occlusive thrombus grew, peaking in size at 30 min, and regressing by 60 min, as revealed by histomorphometric volume reconstruction of the clot. Pre-heparinization greatly reduced clot formation at 10, 30, and 60 min (p<0.01 versus non-heparinized). Homozygous FactorV Leiden mice (analogous to the clinical FactorV Leiden prothrombotic mutation) on a C57Bl/6 background had clot volumes more than twice those of wild-types at 30 min (0.121±0.018 mm3 vs. 0.052±0.008 mm3, respectively; p<0.01). Scanning electron microscopy revealed a clot surface dominated by fibrin strands, in contrast to arterial thrombi which showed a platelet-dominated structure. This new model of DVT presents a quantifiable approach for evaluating thrombosis-related murine transgenic lines and for comparatively evaluating new pharmacologic approaches for prevention of DVT.

Download Full-text